Biotech

All Articles

' All palms on deck' at Lilly as peers target being overweight market

.CEO David Ricks may observe the firms setting up tents at basecamp responsible for Eli Lilly in a t...

Entero laying off personnel, abandoning workplace and stopping briefly R&ampD

.Mattress Liquidators has turned Entero Therapeutics white as a slab. The financial institution boug...

Exelixis goes down ADC after deciding it's no match for Tivdak

.Exelixis is losing hope on its cells element (TF)- targeting antibody-drug conjugate after ending t...

Relay dislikes SHP2 prevention after Genentech leaves

.Three weeks after Roche's Genentech system left an SHP2 inhibitor contract, Relay Rehab has actuall...

Stoke's Dravet disorder med discharged of partial scientific grip

.Stoke Rehabs' Dravet disorder drug has been freed from a partial hold, removing the technique for t...

Fierce Biotech's Gabrielle Masson offers Intense 15 at NYSE

.Fierce Biotech Partner Editor Gabrielle Masson offered the 2024 class of Fierce 15 champions on the...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH possibility

.Novo Nordisk has axed its own once-monthly double GLP-1/ GIP receptor agonist, finishing (PDF) adva...

Daiichi spends Merck $170M to form lung cancer T-cell engager treaty

.Merck &amp Co. has promptly recovered a few of the expenses of its Spear Rehabs purchase, attractin...

BioMarin standstills preclinical gene therapy for heart condition

.After BioMarin performed a spring season tidy of its own pipeline in April, the provider has actual...

Eisai vegetations molecular glue SEED with $1.5 B biobucks handle

.Large Pharmas stay caught to the suggestion of molecular adhesive degraders. The current firm to vi...